In one study with Ad5/3-D24-GM-CSF ± low-dose CPA (to reduce Tregs), treatment with TMZ increased tumor cell autophagy, anti-tumor immunity, and ultimately reduced tumor burden in murine models of xenogeneic prostate cancer (82). The gene discussed is CSF2; the disease is neoplasm.